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Thermostabilization of Viruses via Complex Coacervation
Xue Mi,†a,b Whitney C. Blocher McTigue,†c Pratik U. Joshi,a,b Mallory K. Bunker,a Caryn L. Heldt*a,b 
and Sarah L. Perry*c,d
Widespread vaccine coverage for viral diseases could save the lives of millions of people each year. For viral vaccines to be 
effective, they must be transported and stored in a narrow temperature range of 2-8°C. If temperatures are not 
maintained, the vaccine may lose its potency and would no longer be effective in fighting disease; this is called the cold 
storage problem. Finding a way to thermally stabilize a virus and end the need to transport and store vaccines at 
refrigeration temperatures will increase access to life-saving vaccines. We explore the use of polymer-rich complex 
coacervates to stabilize viruses. We have developed a method of encapsulating virus particles in liquid complex 
coacervates that relies on the electrostatic interaction of viruses with polypeptides. In particular, we tested the 
incorporation of two model viruses; a non-enveloped porcine parvovirus (PPV) and an enveloped bovine viral diarrhea 
virus (BVDV) into coacervates formed from poly(lysine) and poly(glutamate). We identified optimal conditions (i.e., the 
relative amount of the two polypeptides) for virus encapsulation, and trends in this composition matched differences in 
the isoelectric point of the two viruses. Furthermore, we were able to achieve a ~103 – 104-fold concentration of virus into 
the coacervate phase, such that the level of virus remaining in the bulk solution approached our limit of detection. Lastly, 
we demonstrated a significant enhancement of the stability of non-enveloped PPV during an accelerated aging study at 
60°C over the course of a week. Our results suggest the potential for using coacervation to aid in the purification and 
formulation of both enveloped and non-enveloped viruses, and that coacervate-based formulations could help limit the 
need for cold storage throughout the transportation and storage of vaccines based on non-enveloped viruses.
Introduction
According to the World Health Organization (WHO), 
millions of people die from viral infectious diseases each year.1 
One of the most effective methods to prevent viral infection is 
with vaccines. In order for viral vaccines to be effective, they 
must be transported and stored in a “cold chain.”2 A cold chain 
is a system of transporting and storing vaccines at the 
recommended temperature, typically 2-8°C, from the 
manufacturer until the point of use.2,3 If temperatures are not 
maintained, the vaccine may lose its potency and could no 
longer be effective in fighting disease.4 Approximately half of 
the vaccines produced each year are discarded due to poor 
thermal stability.5 The unreliable cold chain system is one of 
the major causes of inadequate immunization coverage in 
developing countries.4 Therefore, developing robust, 
thermostable viral vaccines that are less dependent on the 
cold chain is urgent and crucial for universal access to 
immunizations.
There are three major types of viral-based vaccines 
licensed for human use: live attenuated, inactivated, and 
subunit vaccines.6,7 Live-attenuated vaccines are usually 
produced by extended passage of a disease-causing (wild) 
virus in non-human cell culture to weaken the wild virus.8-10 
The attenuated virus can still replicate and stimulate high 
immunity, but has lost the ability to cause disease. Inactivated 
vaccines are typically treated by chemical or heat inactivation 
to stop virus replication.8-10 In contrast, the inactivated virus 
cannot replicate, but can still produce immunogenicity. 
Subunit vaccines use a component of the virus, such as a 
surface polysaccharide, capsid protein, or nucleic acid, to 
stimulate an immune response.8-10 Typically, live attenuated 
viruses raise the strongest immune response, followed by 
inactivated viruses, and then subunit vaccines; however, the 
stability of these three types of vaccines is in reverse order.6,7 
Thus, live attenuated viral vaccines tend to be the most 
sensitive to temperature changes, and tight temperature 
control is required for them to remain immunogenic.6 There is 
a need to develop versatile methods to improve the thermal 
stability of live attenuated vaccines. 
Various methods have been developed to create 
thermostable viral vaccines, ranging from direct genetic 
modification11,12 to changes in the formulation13,14 However, 
genetically modifying a viral vaccine is labour-intensive, virus-
specific, and may not be accessible for some targets.11,12 A 
more standard method to stabilize vaccine formulations is to 
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add stabilizing excipients.13,14 For example, high molar 
concentrations of sucrose were able to maintain the infectivity 
and in vivo immunogenicity of an adenovirus serotype 5 at 
37°C for 10 days.13 
Further improvements in the thermal stability of virus 
formulations are often achieved via drying by lyophilization, 
spray drying, or foam drying.15,16 Drying aims to slow down the 
physical and chemical degradation of the vaccine. However, 
these methods typically require the presence of sugars (e.g., 
sucrose, mannitol, and trehalose), amino acids, and/or other 
cryoprotectants and bulking agents that tend to hydrogen 
bond with viral capsid proteins and/or viral envelopes to 
entrain surface-bound water and form a stabilizing matrix.15-19 
For example, lyophilized rotavirus vaccines formulated in 
optimized buffer conditions with polyvinyl pyrrolidone as a 
bulking agent, sucrose as a cryoprotectant, and L-arginine and 
glycine as osmolytes, can retain potency for 20 months at 37°C 
and 7 months at 45°C.18 An analogous strategy where viral 
encapsulation in hydrated silica was used in place of an organic 
matrix slowed the infectivity loss of the human enterovirus 
type 71 by six-fold at 37°C for 20 days, or at 40°C for 36 
hours.20 Although such formulation methods show promise for 
thermostabilizing vaccines, the outcomes tend to be the result 
of large-scale trial and error experiments, and there is a need 
for a simple, low-cost, and versatile approach for stabilizing 
viruses.
We propose the use of complex coacervation as a strategy 
for improving the thermal stability of viral vaccines. Complex 
coacervation is an associative liquid-liquid phase separation 
phenomena that results from the electrostatic and entropic 
interactions between oppositely charged macro-ions.21-24 
Complex coacervation has a strong history of use as a method 
of encapsulation in the food and personal care industries,25-30 
and has gained recent attention for use in the fields of drug 
delivery31-35 and gene therapy.36-38 A number of reports have 
focused specifically on the incorporation of proteins into 
complex coacervates, with a goal of protecting proteins 
against degradation39,40 and potentially enhancing protein 
thermal stability. 41
We recently demonstrated the ability of two-polymer 
coacervates to effectively encapsulate proteins with a range of 
different size and charge characteristics.42 Here, we adapt our 
approach, to study the encapsulation and potential for thermal 
stabilization of two model viruses (Figure 1). We characterized 
the complex coacervation of cationic poly(L-lysine)400 (K400) 
and negatively charged poly(D,L-glutamic acid)400 (E400) in the 
presence of a non-enveloped porcine parvovirus (PPV) and an 
enveloped bovine viral diarrhea virus (BVDV) as a function of 
the charge ratio of the two polymers present in solution, and 
quantified the uptake of virus into the coacervate phase. 
Lastly, we perform accelerated aging studies to characterize 
the thermal stability of our coacervate-virus formulations as a 
proof-of-concept for thermostabilizing vaccines of live 
attenuated viruses.
Figure 1. Schematic depiction of virus encapsulation via complex coacervation with two 
oppositely charged polypeptides.
Materials and Methods
Materials
Potassium phosphate monobasic (molecular biology grade, 
≥99.0%) and sodium chloride (NaCl, ACS grade, ≥99.0%) were a 
gift from Millipore Sigma (Burlington, MA). Sodium phosphate 
dibasic heptahydrate (ACS grade, 98.0-102.0%), sodium 
hydroxide (NaOH, ACS grade, ≥97.0%), sodium dodecyl sulfate 
(SDS) and dimethyl sulfoxide (DMSO, BioReagent, >99.7%) 
were purchased from Sigma-Aldrich (St. Louis, MO). 
Hydrochloric acid (HCl, ACS grade, 36.5-38.0%) and (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) 
(≥99.0%) were purchased from Fisher Scientific (Pittsburgh, 
PA). Pierce fluorescent dye 5-(and 6)-carboxy-tetramethyl-
rhodamine succinimidyl ester (NHS-Rhodamine) was 
purchased from Thermo Fisher Scientific (Waltham, MA). 
Thiazolyl blue tetrazolium bromide (MTT) (98%) was 
purchased from Alfa Aesar (Haverhill, MA). Medium essential 
medium (MEM) and Dulbecco’s modified eagle medium 
(DMEM) were purchased from Life Technologies (Carlsbad, 
CA). Polypeptides with a degree of polymerization of 400, 
poly(D,L-glutamic acid) (E400) and poly(L-lysine) (K400), were 
purchased from Alamanda Polymers (Huntsville, AL). The 
polypeptides were used as received without further 
purification. Characterization information for the polypeptides 
is given in Supplemental Table S1.
All aqueous solutions and buffers were prepared using 
purified water with a resistivity of ≥18 MΩ·cm from a 
Nanopure filtration system (Thermo Scientific, Waltham, MA) 
and filtered with a 0.2 µm bottle top filter (VWR, Radnor, PA) 
or a 0.2 µm syringe filter (VWR) prior to use. Phosphate 
buffered saline (PBS) (pH 7.20 ± 0.03) was prepared by 
dissolving 0.21 g potassium phosphate monobasic, 0.73 g 
sodium phosphate dibasic heptahydrate, and 9.0 g NaCl into 
1000 mL Nanopure water. Stock solutions of 10 mM 
polypeptide solutions were prepared on a charged monomer 
basis and adjusted with 1 M HCl and 1 M NaOH to the desired 
pH 8.00 ± 0.03 pH units. Zwitterionic buffer solution of 0.4 M 
HEPES was also adjusted with 1 M HCl and 1 M NaOH to the 
desired pH 8.00 ± 0.03 pH units.
Virus production, purification, and titration
Porcine kidney cells (PK-13, CRL-6489) and bovine 
turbinate cells (BT-1, CRL-1390) were purchased from ATCC. 
Porcine parvovirus (PPV) strain NADL-2, was a gift from Dr. 
Ruben Carbonell (North Carolina State University, Raleigh, NC). 
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Bovine viral diarrhea virus (BVDV) strain NADL was purchased 
from USDA APHIS. PPV was propagated in PK-13 cells, and 
BVDV was propagated in BT-1 cells, as described 
previously,43,44 and stored at −80°C until further use. PPV or 
BVDV were further purified with a Biotech Cellulose Ester 
1,000 kDa dialysis tubing (Rancho Dominguez, CA) and a 
BioRad Econo-Pac 10DG desalting column (Hercules, CA) in PBS 
buffer, as previously described,45 and stored at 4°C until 
further use. 
To determine the concentration of the infectious virus, an 
MTT assay was used. Briefly, either 8 x 104 cells/mL PK-13 cells 
in completed MEM media (to titrate PPV)46 or 2.5 x 105 
cells/mL BT-1 cells in completed DMEM media (to titrate 
BVDV)47 were seeded in a clear, flat-bottom, 96-well plate in a 
volume of 100 µL/well. After one day of incubation, 25 µL/well 
of virus sample was added to the corresponding host cells in 
quadruplicate and serially diluted across the plate. After 6 days 
post-inoculation, 10 μL/well of 5 mg/mL MTT reagent in PBS 
(pH 7.2) was added to the plate. After 4 hours, 100 μL/well of 
solubilizing agent, 10% SDS in 0.01 M HCl (pH 2.5), was added 
to the plate. After 12 to 24 hours, plates were read at 550 nm 
in a Synergy Mx monochromator-based multimode microplate 
reader (Winooski, VT). The virus dilution that killed 50% of the 
cells is stated as the virus titer MTT50.44 A similar procedure 
was used to quantify the cytotoxicity of the coacervates and 
the individual peptides (see SI for details).
Formation of virus-containing complex coacervates
Virus-containing complex coacervate samples were formed 
by first pipetting water, and then HEPES buffer into a 1.7 mL 
microcentrifuge tube, followed by the virus (PPV or BVDV), 
K400, and E400. The samples were vortexed for 5 seconds after 
the addition of each polypeptide to ensure fast and complete 
mixing. The recipes for each sample of PPV- and BVDV-
containing complex coacervates are detailed in Supplemental 
Tables S2 and S3, respectively. A typical experiment contained 
a total volume of 240 µL and maintained a constant total 
polymer concentration of 7 mM (on a monomer basis) while 
varying the ratio of K400 to E400. The concentration of virus was 
also maintained constant at 4, 5, and 6 log (MTT50/mL) for PPV 
and 4 and 5 log (MTT50/mL) for BVDV, and all experiments 
were performed in 10 mM HEPES buffer, pH 8.0. All virus-
containing complex coacervates were prepared immediately 
before use and studied at room temperature. All experiments 
were performed in triplicate.
Virus complex coacervates characterization and quantification
We used turbidity to qualitatively measure the formation 
of the virus-containing complex coacervates. Briefly, turbidity 
was measured by placing 100 µL of the sample into a clear, 
flat-bottom, 96-well plate and measuring the absorbance at 
562 nm using a Synergy Mx monochromator-based multimode 
microplate reader (Winooski, VT).42,48 The measured signal was 
referenced against a control well containing only Nanopure 
water and HEPES buffer. Samples were then examined using 
an Olympus IX51 microscope with a DP72 camera (Center 
Valley, PA) to confirm the presence or absence of 
coacervation, and the 100 µL aliquot was recovered for 
subsequent use in the infectivity assay. Only two 
concentrations of BVDV coacervates were studied due to the 
initial concentration of enveloped BVDV propagated being 
lower than PPV.
Viruses were also labelled with a fluorescent dye NHS-
Rhodamine that absorbs visible green light at a wavelength of 
552 nm and emits orange-red visible light at 575 nm to 
confirm the presence of the virus in the coacervate phase. 1 
mL of purified virus solutions (8 log PPV or 7 log BVDV) were 
incubated with 10 mg/mL NHS-Rhodamine in DMSO solution 
(2.15 μL for PPV and 6.5 μL for BVDV) for 1 hour at room 
temperature. Excessive non-tagged fluorescent dye was 
removed with a BioRad Econo-Pac 10DG desalting column. The 
fluorescently labelled virus was used immediately to form the 
virus coacervate, as described above. An aliquot of 100 μL of 
tagged virus coacervates was transferred to one well of a 96-
well plate and examined with an Olympus IX51 microscope. 
The coacervates droplets were imaged using both brightfield 
and fluorescence modes and analysed with ImageJ. 
An MTT virus infectivity assay was used to quantify the 
amount of virus present in both the coacervate and the 
supernatant phases.44 The 240 μL sample containing the 
complex coacervate and virus in the microcentrifuge tube was 
centrifuged using an ST16R Centrifuge (Thermo Scientific, 
Asheville, NC) at 14,000 rpm (21,475 × g) for 20 min at 15°C to 
separate the supernatant from the dense coacervate phase. 
Following centrifugation, the supernatant volume was 
carefully measured and transferred into a new microcentrifuge 
tube via pipetting. A volume of 220 µL of 2 M NaCl solution 
was added to the dense coacervate phase (transparent gel) to 
dismantle the coalesced virus coacervate, followed by 
vortexing. The concentration of virus in both the supernatant 
and dismantled coacervate was then titrated by the MTT 
assay. The volume of the coacervate phase was neglected, 
though we estimated that the maximum volume of coacervate 
formed was approximately ~1 µL. These values were then used 
to calculate the partitioning of the virus into the complex 
coacervate phase. The partition coefficient (K) was calculated 
as: 
 (1)𝐾 = 𝐶c𝐶s
where Cc is the virus concentration in the coacervate phase, 
and Cs is the virus concentration in the supernatant phase.
Virus thermal stability study
Thermal stability studies were performed using samples 
where maximal virus partitioning was observed, (i.e., a charge 
fraction of 0.5 for PPV and 0.6 for BVDV). A microcentrifuge 
tube containing either the PPV dense coacervate phase or 
purified PPV was capped and wrapped in Parafilm and put in a 
digital dry bath (USA Scientific, Ocala, FL) at 60°C. The BVDV 
complex coacervate and purified BVDV were similarly put in 
the dry bath at 40°C. At each time point, a tube containing 
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Table 1. Model virus properties, including size, isoelectric point (pI), and related human viruses.
Virus Capsid Family
Nucleic 
acid
Size (nm) pI
Related human 
viruses
References
Porcine 
parvovirus (PPV)
Non-
enveloped
Parvoviridae ssDNA 18-26 4.8-5.1
B-19 human 
parvovirus
43,49,50
Bovine viral 
diarrhea virus 
(BVDV)
Enveloped Flaviviridae ssRNA 40-60 4.3-4.5 Hepatitis C 43,49,51
~1 µL of the dense, virus-containing coacervate sample was 
removed from the heating block and dismantled in 220 µL of 2 
M NaCl. A purified virus sample was also removed from the 
heat at the same time. The experiment was performed in 
triplicate. Both samples were then titrated with the MTT assay 
to determine the remaining infectious virus concentrations. A 
log reduction value (LRV) of the virus was calculated as:
(2)𝐿𝑅𝑉 = ― log10(𝐶f𝐶i)
where Cf is the final virus concentration after heat treatment, 
and the Ci is the initial virus concentration.
The lifetime of infectious PPV particles τ was determined 
using a simple model for infectivity loss:13 
(3)n(t) = n0e ―𝑡/𝜏
where t is the length of thermal treatment, n(t) is virus titer at 
t, n0 is the initial virus titer, and τ is the inverse decay rate 
corresponding to the mean lifetime of an infectious viral 
particle. 
Statistical Analysis
Statistical analysis was performed using an unpaired, two-
tailed Student’s t test. An asterisk (*) denotes p < 0.05 
between samples. 
Results and Discussion
The goal of this work was to determine if complex 
coacervation could be used to encapsulate and thermally 
stabilize viruses. To this end, we studied the encapsulation and 
stabilization of two model viruses, non-enveloped PPV and 
enveloped BVDV. This approach allowed us to explore 
potential differences between enveloped and non-enveloped 
viruses. 
Encapsulation of virus
Previous reports on protein encapsulation using 
coacervates emphasized the importance of electrostatic 
Figure 2. (a,d) Brightfield, (b,e) fluorescence, and (c,f) merged optical micrographs of (a-c) PPV- and (d-f) BVDV-containing coacervate droplets, demonstrating virus encapsulation.
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Figure 3. Turbidity of the encapsulated virus as a function of the polymer charge 
fraction associated with cationic K400 for coacervates prepared with different 
concentrations of (a) PPV and (b) BVDV. All data points are the average of three 
separate tests, and error bars represent the standard deviation.
interactions in driving protein incorporation.42,52-57 Therefore, 
it is important to consider the charge state of the viruses used 
in our study. Table 1 outlines some of the physical properties 
of the chosen viruses. Notably, both viruses have an acidic 
isoelectric point,43 meaning that the particles will carry a net 
negative charge at most physiologically-relevant solution 
conditions, and will become more negatively charged at higher 
pH conditions.
However, in the context of complex coacervation, we must 
balance the charge state of our viruses with that of the two 
complexing polypeptides.42 Therefore, because both PPV58 and 
BVDV are stable at pH 8.0,59 we elected to perform our 
experiments at a solution pH of 8.0 using 10 mM HEPES as a 
neutral, zwitterionic buffer. This solution condition maximizes the 
negative charge of the virus particles while limiting the loss of 
charge from the poly(lysine). Furthermore, our previous efforts 
with proteins had indicated that protein encapsulation 
decreased dramatically at higher ionic strength 
conditions.42,53,54 Therefore, experiments were performed in 
the absence of added salt. 
In order to identify optimal conditions for viral 
encapsulation, we performed coacervation experiments at 
levels of constant virus concentration and constant total 
polypeptide concentration while varying the relative amounts 
of the polycation K400 and polyanion E400. Figure 2 shows the 
characteristic optical micrographs of the resulting samples, 
prepared with the fluorescently labelled virus. Colocalization 
of the fluorescent signal with the droplets confirmed the 
successful incorporation of both PPV and BVDV into our 
complex coacervates. It should be noted that our study did not 
aim to create a coacervate formulation with a specified droplet 
size, and the coacervate droplets in our samples coalesce over 
time. Careful consideration of these types of physical 
properties would be necessary for translation of this method 
into actual practice, but are beyond the scope of the current 
work.
Turbidity measurements, along with visual inspection via 
optical microscopy, were used to identify the presence or 
absence of phase separation (Figure 3). We observed a general 
increase in the turbidity signal with increasing virus 
concentration, consistent with an increase in the total volume 
of coacervate present, although the qualitative nature of 
turbidity is such that we cannot decouple an increase in the 
number of coacervate droplets from changes in droplet size.
The maximum turbidity signal for all samples was observed 
at a cationic polymer charge fraction below 0.50, 
corresponding to “net negative” conditions. This result is 
somewhat unexpected, as the acidic pI of both viruses would 
suggest that optimal coacervation would be expected at a “net 
positive” polymer ratio.42,55,57 However, the turbidity signal for 
all but one of our samples also showed a bimodal shape, with 
the second peak located at higher charge fractions. This 
bimodal signal likely indicates a heterogeneous population of 
viruses, where each turbidity peak represents a distinct virus 
population, which is common,60 and could explain the 
unexpected results. 
While optical microscopy and turbidity confirmed the 
successful formation of virus-containing coacervates, it did not 
provide quantitative information on the amount of virus 
sequestered in the coacervates. Therefore, we employed an 
MTT cell viability assay to quantify the concentration of 
infectious virus in both the supernatant and coacervate 
phases. The plots of virus titer as a function of coacervate 
charge stoichiometry in Figure 4 showed strong extraction of 
both PPV and BVDV into the coacervate phase that was 
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Figure 4. Live virus titration as a function of the polymer charge fraction associated with cationic K400 for both the supernatant (open symbols) and coacervate (closed symbols) 
phases for samples prepared with different total starting concentrations of (a-c) PPV and (d-e) BVDV. All data points are the average of three separate tests, and error bars 
represent the standard deviation.
matched by a commensurate decrease in the virus titer for the 
supernatant phase. 
Interestingly, we only observed a single peak in our virus 
titer data, corresponding to the second peak in the turbidity 
measurements (i.e., the peak at higher, “net positive” charge 
Figure 5. Partition coefficient as a function of the polymer charge fraction associated with cationic K400 for coacervates prepared with different concentrations of (a-c) PPV and 
(d,e) BVDV. All data points are the average of three separate tests, and error bars represent the standard deviation. 
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fractions). For PPV, this maximum sequestration was observed 
near a charge ratio 0.5 (Figure 4a-c), while for BVDV, the 
maximum occurred near a charge ratio of 0.6 (Figure 4d,e). 
This difference in the peak location is likely explained by the 
fact that pI of BVDV is more acidic than PPV (Table 1), 
suggesting the potential for a higher net charge at our 
experimental conditions of pH = 8.0. 
Figure 5 plots the logarithmic value of the partition 
coefficient ln(K), where a positive value indicates that the viral 
particles favoured the coacervate phase, while a negative 
value indicates that the viral particles remained in the 
supernatant phase. While the trends in partition coefficient 
derive from those already described in terms of viral titer, 
what is particularly noteworthy is the magnitude of the 
partition coefficient. We observed a trend of increasing 
maximum partition coefficient with the initial viral 
concentration that achieved 6.2x104 fold increase for PPV and 
2.4x103 fold increase for BVDV. This ability to both sequester 
and concentrate virus has tremendous potential for 
applications related to virus purification and formulation. For 
example, an aqueous two-phase system of poly(ethylene 
glycol) and salt was only able to achieve an approximate 10-
fold partitioning of bacteriophage M13.61
These observed trends in virus titer and partitioning are 
also matched by a calculation of the virus recovery into the 
coacervate phase (Supplemental Figure S1). While our results 
indicate 100% recovery of PPV into the coacervate phase, we 
were only able to recover approximately 50% of BVDV. This is 
likely due to the lower stability of the enveloped BVDV in the 
high ionic strength conditions used to dissolve the coacervate, 
as high concentrations of salt can cause leakage in the viral 
envelope membrane.62 Alternative strategies for destabilizing 
the coacervate could potentially circumvent this challenge, but 
are beyond the scope of the current work.
Thermal stability of encapsulated vs. free virus
To demonstrate the effect of complex coacervates on the 
stability of viruses against high temperatures, we sought to 
identify accelerated aging conditions for a stability study, using 
conditions where the viruses would become completely 
inactivated over a reasonable experimental lifetime. Literature 
reports on the stability of purified solutions of virus suggested 
the use of 60°C for PPV, as a 1 log loss of infectivity was 
observed for this non-enveloped virus after 1 hour.63 For 
BVDV, we selected temperature of 40°C, having observed a 
50% loss of infectivity at 37°C for 6 hours.64
We performed stability studies, comparing solutions of 
free virus in aqueous solution with an equivalent amount of 
total virus encapsulated in our optimum coacervate 
conditions. At each time point, a sample of both free and 
encapsulated virus was removed from heat, the coacervate 
phase was disassembled by the addition of 2 M NaCl to the 
coacervate sample, and the viral titer was determined 
(Supplemental Figure S2). From these data, we calculated the 
loss of activity over time as a log reduction value (LRV). 
For PPV, we observed significant retention of activity due 
to encapsulation (Figure 6a). After 1 day at 60°C, encapsulated 
PPV effectively maintained its viral titer, only losing 1.0 log ± 
0.1 log (MTT50/mL). In comparison, free PPV showed a LRV of 
2.9 log ± 0.3 log (MTT50/mL) after 1 day. Moreover, free PPV in 
solution was found to be completely inactivated after 7 days 
under 60°C, with an LRV of 5.9 ± 0.5 log (MTT50/mL), while 
encapsulated PPV only suffered a titer loss of 2.7 log ± 0.1 log 
(MTT50/mL) after 7 days. 
Figure 6. Thermal stability defined as the log reduction value (LRV) as a function of time 
for free and encapsulated (a) PPV and (b) BVDV. All data points are the average of 
three separate tests, and error bars represent the standard deviation. Lines are a guide 
for the eye. An asterisk (*) denotes p < 0.05 comparing encapsulated and free samples 
at the same time point.
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We can further use a simple lifetime model to calculate 
infectivity loss (Eq. 3). This model assumes the infectious viral 
particles degraded from infectious to a disrupted state at a 
constant rate and was fit to the titer data (Supplemental 
Figure S2a). Based on this model, we determined a lifetime for 
our encapsulated PPV to be 14 days at 60°C, which is 
significantly longer than the 4-day lifetime of free PPV at 60°C. 
Using the Simonelli and Dresback’s Q10 factor for shelf-life 
determination and a Q10 value of 2, 7 days at 60°C is 
equivalent to 3 months at 22°C. While a 2 LRV lose would be 
too much for an FDA approved vaccine, this method shows 
promise as a method to thermally stabilize non-enveloped 
viruses at room temperature.65,66
We hypothesize that the enhanced thermal stability of 
encapsulated PPV compared to the free PPV could be 
attributed to crowding effects associated with the high 
concentrations of polymer and virus present in the coacervate. 
These types of excluded volume effects typically disfavour 
protein unfolding and denaturation events that could be 
associated with loss of viral activity.40,67 The main driving force 
for viral capsid protein unfolding is believed to be the high 
conformational entropy of the denatured state,68 as the 
flexible unfolded state has more conformational degrees of 
freedom than the compact folded state. The limited volume of 
the crowded coacervate environment would therefore 
minimize the number of accessible conformational degrees of 
freedom for the unfolded state, and hence stabilize the native 
state of the viral protein.68-70 While there is also the potential 
for enthalpic contributions to protein stability,41,71,72 
exploration of these effects would require modulation of the 
coacervate materials, and is beyond the scope of the current 
work.
Given the promising improvements in stability seen for PPV 
(a non-enveloped virus), we similarly explored the stability of 
BVDV as a model non-enveloped virus (Figures 6b and S2b). 
However, complex coacervates offered no protection for BVDV 
against high temperatures. In fact, the data showed that 
encapsulated samples inactivated faster than free BVDV. We 
hypothesize that the lipid envelope surrounding the capsid 
provides a similar entropic stabilization effect for BVDV, as was 
described in the context of the coacervate for PPV. However, 
interactions between the coacervate and the lipid bilayer 
could adversely affect the stability of both the membrane and 
the virus. Poly(lysine) is known to penetrate negatively 
charged lipid bilayers,73 and can have cytotoxic effects at high 
concentrations. However, while a dose-dependent poly(lysine) 
cytotoxicity was observed for both the PK-13 and BT-1 cells 
used in this study, it is interesting that the coacervate showed 
no toxicity with the BT-1 cells used alongside BVDV, while 
some toxicity was observed for PK-13 cells (Supplemental 
Figure S3). However, viral envelopes do not play precisely the 
same role as the membranes of more complex organisms, and 
potential interference with the BVDV envelope could explain 
the nearly 2 log difference in initial activity observed for BVDV, 
as well as the 50% recovery levels of BVDV in coacervates 
(Supplemental Figure S1). It is possible that these adverse 
effects could be overcome by a change in coacervate materials 
and/or experimental methodology. However, such 
investigations are beyond the scope of the current work.
Conclusions
In summary, we explored the encapsulation of two model 
viruses, a non-enveloped PPV and an enveloped BVDV, into 
polypeptide-based complex coacervates. This first proof-of-
concept demonstration of viral encapsulation highlighted the 
tremendous potential for using complex coacervation as a 
strategy for extracting virus from aqueous solution with near 
100% recovery for non-enveloped viruses. Furthermore, strong 
partitioning of the viruses into the coacervate phase allowed 
for an increase in virus concentration on the order of 
6.2x104/2.4x103 fold for PPV/BVDV. While these two aspects 
of downstream viral processing each have significant potential 
to impact strategies for the purification, concentration, and 
formulation of viruses, we also demonstrated a significant 
enhancement in the thermal stability of the non-enveloped 
PPV. Although more detailed studies on the intermolecular 
interactions driving these effects is needed, across a range of 
additional viruses, our results suggest that complex 
coacervation could help to improve the thermal stability of at 
least non-enveloped viral vaccines, thereby decreasing the 
need for a cold chain to maintain their efficacy, decreasing 
costs, and improving accessibility. 
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